Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico October 31, 2025 André Leão Dantas, Lara Moreira Jalles Milani, Saulo Gabriel Moreira Falci et al.
Psilocybin, a psychedelic compound from Psilocybe mushrooms, shows promise for chronic pain management by modulating serotonin receptors and promoting neuroplasticity. A scoping review of 20 studies (9 published, 11 ongoing trials, 5 patents) found doses of 5 to 25 mg, given singly or with psychotherapy, reduced pain intensity and improved mood and quality of life. Animal model results were mixed, with some showing significant analgesia and others no effect. Patents reveal industrial interest in microdosing and controlled-release formulations for fibromyalgia, neuropathic pain, and phantom pain. The evidence suggests psilocybin is a promising alternative, but robust clinical trials are needed to confirm efficacy and safety.